NCT03367026: REHSI

Reducing Elevated Heart Rate in Patients With Severe Sepsis by Ivabradine

Status unknown NA Last updated 8 December 2017

What this trial tests

NA trial testing Ivabradine Oral Product in Sepsis, Severe in 70 participants. Status unknown.

Timeline

1 January 2018

Primary endpoint
31 December 2020

30 June 2021

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	70
Start date	1 January 2018
Primary completion	31 December 2020
Estimated completion	30 June 2021

Drugs / interventions tested

• Ivabradine Oral Product — full drug profile →

Conditions studied

• Sepsis, Severe — all drugs for Sepsis, Severe →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 80, any sex, with Sepsis, Severe. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

REHSI is a prospective, multi-center, open label, randomized, controlled two arms, to evaluate the ability of ivabradine to reduce an elevated heart rate in septic shock patients. The primary end point is the reduction of heart rate within 24 hours. This trial will randomize 70 patients (men and women, aged ≥ 18 years) with newly diagnosed Septic Shock (despite adequate fluid resuscitation, were still requiring high-dose norepinephrine (NE) to maintain a mean arterial pressure (MAP) ≥65 mmHg , and had a tachycardia \>100 beats per minute (bpm). Treatment period will last 4 days. All patients will be followed for up to six months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.